Assessment of cobalt 57 tagged bleomycin as a clinical aid in staging of head and neck carcinoma

Charles W Cummings, Steven M. Larson, Robert A. Dobie, Ernest A. Weymuller, Thomas G. Rudd, Augusto Merello

Research output: Contribution to journalArticle

Abstract

Critical assessment of head and neck cancer with respect to staging has, on occasion, been disappointingly ineffective. We have attempted to correlate the incidence of measure-able uptake of cobalt 57 tagged bleomycin by primary squamous cell carcinoma and metastatic cervical lymph nodes. Forty-six cases have been evaluated with respect to histo-pathological confirmation of the suspected metastatic disease. We have found that this diagnostic measure increases our acumen in staging of head and neck cancer. The relevance of the Co-Bleo scans as a diagnostic aid is reported in 46 cases. Malignant tumors greater than 2 cm in size appear to demonstrate active uptake of the imaging agent. Small tumor size and excess background radioactivity contribute to the false-negatives (17%). Inflammatory conditions or benign tumors of the salivary apparatus may result in minimal uptake, thus, a false-positive result (10%). An increase in the radioactivity of the Co-Bleo may enhance the benefits of this procedure in the search for an undiagnosed primary, as well as undiagnosed local or distant metastases.

Original languageEnglish (US)
Pages (from-to)529-537
Number of pages9
JournalLaryngoscope
Volume91
Issue number4
StatePublished - 1981
Externally publishedYes

Fingerprint

Bleomycin
Cobalt
Neck
Head
Head and Neck Neoplasms
Carcinoma
Radioactivity
Neoplasms
Squamous Cell Carcinoma
Lymph Nodes
Neoplasm Metastasis
Incidence

ASJC Scopus subject areas

  • Otorhinolaryngology

Cite this

Cummings, C. W., Larson, S. M., Dobie, R. A., Weymuller, E. A., Rudd, T. G., & Merello, A. (1981). Assessment of cobalt 57 tagged bleomycin as a clinical aid in staging of head and neck carcinoma. Laryngoscope, 91(4), 529-537.

Assessment of cobalt 57 tagged bleomycin as a clinical aid in staging of head and neck carcinoma. / Cummings, Charles W; Larson, Steven M.; Dobie, Robert A.; Weymuller, Ernest A.; Rudd, Thomas G.; Merello, Augusto.

In: Laryngoscope, Vol. 91, No. 4, 1981, p. 529-537.

Research output: Contribution to journalArticle

Cummings, CW, Larson, SM, Dobie, RA, Weymuller, EA, Rudd, TG & Merello, A 1981, 'Assessment of cobalt 57 tagged bleomycin as a clinical aid in staging of head and neck carcinoma', Laryngoscope, vol. 91, no. 4, pp. 529-537.
Cummings CW, Larson SM, Dobie RA, Weymuller EA, Rudd TG, Merello A. Assessment of cobalt 57 tagged bleomycin as a clinical aid in staging of head and neck carcinoma. Laryngoscope. 1981;91(4):529-537.
Cummings, Charles W ; Larson, Steven M. ; Dobie, Robert A. ; Weymuller, Ernest A. ; Rudd, Thomas G. ; Merello, Augusto. / Assessment of cobalt 57 tagged bleomycin as a clinical aid in staging of head and neck carcinoma. In: Laryngoscope. 1981 ; Vol. 91, No. 4. pp. 529-537.
@article{c68b942079d14020bddac792acdaefa4,
title = "Assessment of cobalt 57 tagged bleomycin as a clinical aid in staging of head and neck carcinoma",
abstract = "Critical assessment of head and neck cancer with respect to staging has, on occasion, been disappointingly ineffective. We have attempted to correlate the incidence of measure-able uptake of cobalt 57 tagged bleomycin by primary squamous cell carcinoma and metastatic cervical lymph nodes. Forty-six cases have been evaluated with respect to histo-pathological confirmation of the suspected metastatic disease. We have found that this diagnostic measure increases our acumen in staging of head and neck cancer. The relevance of the Co-Bleo scans as a diagnostic aid is reported in 46 cases. Malignant tumors greater than 2 cm in size appear to demonstrate active uptake of the imaging agent. Small tumor size and excess background radioactivity contribute to the false-negatives (17{\%}). Inflammatory conditions or benign tumors of the salivary apparatus may result in minimal uptake, thus, a false-positive result (10{\%}). An increase in the radioactivity of the Co-Bleo may enhance the benefits of this procedure in the search for an undiagnosed primary, as well as undiagnosed local or distant metastases.",
author = "Cummings, {Charles W} and Larson, {Steven M.} and Dobie, {Robert A.} and Weymuller, {Ernest A.} and Rudd, {Thomas G.} and Augusto Merello",
year = "1981",
language = "English (US)",
volume = "91",
pages = "529--537",
journal = "Laryngoscope",
issn = "0023-852X",
publisher = "John Wiley and Sons Inc.",
number = "4",

}

TY - JOUR

T1 - Assessment of cobalt 57 tagged bleomycin as a clinical aid in staging of head and neck carcinoma

AU - Cummings, Charles W

AU - Larson, Steven M.

AU - Dobie, Robert A.

AU - Weymuller, Ernest A.

AU - Rudd, Thomas G.

AU - Merello, Augusto

PY - 1981

Y1 - 1981

N2 - Critical assessment of head and neck cancer with respect to staging has, on occasion, been disappointingly ineffective. We have attempted to correlate the incidence of measure-able uptake of cobalt 57 tagged bleomycin by primary squamous cell carcinoma and metastatic cervical lymph nodes. Forty-six cases have been evaluated with respect to histo-pathological confirmation of the suspected metastatic disease. We have found that this diagnostic measure increases our acumen in staging of head and neck cancer. The relevance of the Co-Bleo scans as a diagnostic aid is reported in 46 cases. Malignant tumors greater than 2 cm in size appear to demonstrate active uptake of the imaging agent. Small tumor size and excess background radioactivity contribute to the false-negatives (17%). Inflammatory conditions or benign tumors of the salivary apparatus may result in minimal uptake, thus, a false-positive result (10%). An increase in the radioactivity of the Co-Bleo may enhance the benefits of this procedure in the search for an undiagnosed primary, as well as undiagnosed local or distant metastases.

AB - Critical assessment of head and neck cancer with respect to staging has, on occasion, been disappointingly ineffective. We have attempted to correlate the incidence of measure-able uptake of cobalt 57 tagged bleomycin by primary squamous cell carcinoma and metastatic cervical lymph nodes. Forty-six cases have been evaluated with respect to histo-pathological confirmation of the suspected metastatic disease. We have found that this diagnostic measure increases our acumen in staging of head and neck cancer. The relevance of the Co-Bleo scans as a diagnostic aid is reported in 46 cases. Malignant tumors greater than 2 cm in size appear to demonstrate active uptake of the imaging agent. Small tumor size and excess background radioactivity contribute to the false-negatives (17%). Inflammatory conditions or benign tumors of the salivary apparatus may result in minimal uptake, thus, a false-positive result (10%). An increase in the radioactivity of the Co-Bleo may enhance the benefits of this procedure in the search for an undiagnosed primary, as well as undiagnosed local or distant metastases.

UR - http://www.scopus.com/inward/record.url?scp=0019425942&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019425942&partnerID=8YFLogxK

M3 - Article

C2 - 6163936

AN - SCOPUS:0019425942

VL - 91

SP - 529

EP - 537

JO - Laryngoscope

JF - Laryngoscope

SN - 0023-852X

IS - 4

ER -